IIC
EBS icon

Integrated Investment Consultants’s Emergent Biosolutions EBS Stock Holding History

Integrated Investment Consultants’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,123
Closed -$251K – 264
2022
Q1 		$251K Buy
6,123
+151
+3% +$6.66K 0.07% 251
2021
Q4 		$260K Sell
5,972
-7
-0.1% -$317 0.07% 254
2021
Q3 		$299K Buy
5,979
+64
+1% +$3.88K 0.09% 212
2021
Q2 		$373K Buy
5,915
+2,182
+58% +$140K 0.11% 169
2021
Q1 		$347K Buy
3,733
+197
+6% +$20.2K 0.12% 169
2020
Q4 		$317K Buy
3,536
+17
+0.5% +$1.56K 0.12% 158
2020
Q3 		$364K Buy
+3,519
New +$379K 0.17% 109
2020
Q2 		– Sell
-3,615
Closed -$209K – 171
2020
Q1 		$209K Buy
+3,615
New +$208K 0.12% 128

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Integrated Investment Consultants's EBS Position: Q2 2022 in Review

Integrated Investment Consultants sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 6,123 shares — an estimated $251K sold.

Integrated Investment Consultants first reported a position in EBS in Q1 2020 and held it in 8 quarters. The position peaked at $373K in Q2 2021. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Integrated Investment Consultants reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Integrated Investment Consultants sold 6,123 Emergent Biosolutions shares in Q2 2022, an estimated $251K.
  • Integrated Investment Consultants first reported a position in Emergent Biosolutions in Q1 2020 and held it in 8 quarters.
  • Integrated Investment Consultants's Emergent Biosolutions position peaked at $373K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Integrated Investment Consultants's 13F filing for Q2 2022, filed 19 Jul 2022.